U.S. stocks on the move: Agios surges on October 19 due to sickle cell disease review and mitapivat.

Bitget

News

Bitget异动解读2026/10/19 17:45

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Agios October 19th Surge Interpretation

Keywords: Sickle cell disease review, mitapivat

On November 1st, the U.S. Food and Drug Administration is expected to make a decision on Agios's application for mitapivat to treat sickle cell disease. This application has received priority review, and Agios is seeking accelerated approval. Developments in this regulatory process have become a catalyst for the recent rise in the stock price.

(Disclaimer: This content is summarized from publicly available information using AI technology and is for reference only. It does not constitute investment advice.)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

If the agreement is implemented, the total scale of cooperation between the two parties will reach $90 billions. The relevant negotiations involve the second building of the Monarch data center campus, which provides 460MW of computing power and adopts NVIDIA’s latest generation Vera Rubin chips. In addition, Anthropic has also obtained the priority negotiation rights for the third building in the Monarch campus plan.

华尔街见闻•2026/10/19 20:51